Clinical Trials

406 enrolled

Sarcoma, Ewing, Osteosarcoma

NCT06220032 2026-01-05

HO170DLBCL

Phase 3 Recruiting

324 enrolled

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT06835049 2025-12-30

TNT-HYPE

24 enrolled

Phase 1 Active not recruiting

Hyperthermia, Sarcoma

NCT01746238 2025-12-19

Bevacizumab/Doxorubicin/Radiation for Sarcoma

14 enrolled

Phase 2 Active not recruiting

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

115 enrolled

Rhabdomyosarcoma

NCT05099666 2025-12-09

Bone Neoplasms, Sarcoma

NCT07243626 2025-11-24

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

15 enrolled

NCT07049848 2025-11-20

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

50 enrolled

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

40 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT03805022 2025-10-02

CIRSARC

Phase 3 Recruiting

351 enrolled

NCT04776525 2025-08-14

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

49 enrolled

NCT04874311 2025-08-13

TRUST

80 enrolled

Tertiary Lymphoid Structures, Neoplasm Metastasis, Sarcoma

NCT04968106 2025-08-13

TORNADO

66 enrolled

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

134 enrolled

Phase 3 Active not recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT00470223 2025-06-08

OS2006

318 enrolled

Phase 2 Active not recruiting

Sarcoma, Osteosarcoma

NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

27 enrolled

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT06268457 2025-04-02

Embodesmo

Recruiting

20 enrolled

Desmoid Tumors

NCT06524583 2025-03-30

L-UteCIN

198 enrolled

Phase EARLY_PHASE1 Terminated

Leiomyosarcoma Uterus

NCT04213794 2025-02-20

TOASTIT

2 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

NCT04055753 2024-12-04

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

Active not recruiting

24 enrolled

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

197 enrolled

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT04535713 2024-07-05

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

260 enrolled

Phase NA Active not recruiting

NCT06451302 2024-06-11

Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

100 enrolled

Sarcoma, Ewing

NCT04625907 2024-05-23

FaR-RMS

Phase 1/2 Recruiting

1,672 enrolled

Rhabdomyosarcoma

NCT05057130 2024-04-01

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Phase 2/3 Recruiting

50 enrolled

Bone Neoplasms, Neoplasms, Connective Tissue, Sarcoma, Osteosarcoma, Neoplasms, Connective and Soft Tissue

NCT03056001 2023-11-18

Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma

30 enrolled 22 charts

NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

73 enrolled 11 charts

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2 Terminated

7 enrolled 9 charts

GenitourinarySarcoma

Bladder Adenocarcinoma

NCT03009201 2023-08-16

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Phase 1 Completed

16 enrolled

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Sarcoma, Disorders of Sex Development, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00667342 2023-08-07

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

43 enrolled 25 charts

Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT03317457 2023-06-15

MEDISARC

103 enrolled

NCT00346125 2022-12-15

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Phase NA Completed

70 enrolled

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02531308 2022-09-28

DLBCL

Phase 2 Terminated

5 enrolled 5 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT04012827 2022-09-07

Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Phase 2 Unknown

108 enrolled

NCT03042819 2021-12-09

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Phase 1 Completed

25 enrolled

NCT02888665 2021-05-26

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Completed

37 enrolled 15 charts

NCT02448537 2021-03-03

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

42 enrolled 11 charts

NCT03698227 2020-07-15

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Phase 2 Terminated

2 enrolled

NCT04356872 2020-07-14

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Phase 2 Unknown

45 enrolled

NCT01446809 2020-04-13

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Phase NA Completed

23 enrolled 16 charts